VEGFA and cancer: On the contrary, while control tumour xenografts showed a diffuse, strong and easily detectable immunoreactivity to the anti-VEGF antibody within cancer cells (Figure 6B), VEGF immunostaining weakly changed in MTD-treated samples (Figure 6D) and remained unaltered in the metronomic therapy-treated ones (Figure 6F and 6H).